Exelixis, Inc. EXEL
The biggest changes in the 10-K filed Feb 10, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
Big change, FY to Jan 2, 2026 vs Jan 3, 2025
The MD&A has no sentence that names a cause for this change.
Net income
Big change, FY to Jan 2, 2026 vs Jan 3, 2025
The MD&A has no sentence that names a cause for this change.
Cash from operations
Big change, FY to Jan 2, 2026 vs Jan 3, 2025
The MD&A has no sentence that names a cause for this change.
Revenue
Change, FY to Jan 2, 2026 vs Jan 3, 2025
“The increase in sales volume was largely driven by refills, reflecting the longer duration of therapy for the combination of CABOMETYX with nivolumab, and an increase in related market share reflecting the continued evolution of the metastatic RCC and NET treatment landscapes.”
Read it in the 10-K
“Royalty revenues increased primarily as a result of an increase in Ipsen’s net sales of cabozantinib outside of the U.S. and Japan.”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2026 +7.0%
“The increase in sales volume was largely driven by refills, reflecting the longer duration of therapy for the combination of CABOMETYX with nivolumab, and an increase in related market share reflecting the continued evolution of the metastatic RCC and NET treatment landscapes.”
Read it in the FY 2026 10-K“Royalty revenues increased primarily as a result of an increase in Ipsen’s net sales of cabozantinib outside of the U.S. and Japan.”
Read it in the FY 2026 10-K -
FY 2025 +18.5%
“The increase in sales volume is largely driven by refills, reflecting the longer duration of therapy for this combination, and an increase in related market share reflecting the continued evolution of the metastatic RCC, HCC and DTC treatment landscapes.”
Read it in the FY 2025 10-K“Royalty revenues increased primarily as a result of an increase in Ipsen’s net sales of cabozantinib outside of the U.S. and Japan.”
Read it in the FY 2025 10-K
Operating margin
0 of 2 years explained-
FY 2026 +9.7 pts
The FY 2026 MD&A has no sentence that names a cause for this change.
-
FY 2025 +18.5 pts
The FY 2025 MD&A has no sentence that names a cause for this change.
Net income
0 of 2 years explained-
FY 2026 +50.1%
The FY 2026 MD&A has no sentence that names a cause for this change.
-
FY 2025 +150.9%
The FY 2025 MD&A has no sentence that names a cause for this change.
Cash from operations
0 of 2 years explained-
FY 2026 +26.3%
The FY 2026 MD&A has no sentence that names a cause for this change.
-
FY 2025 +110.0%
The FY 2025 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.